X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK India: The leader strikes back - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 27, 2002

    GSK India: The leader strikes back

    A look at the operating performance graph of GSK for the last five years would explain the reason for a complete restructuring exercise undertaken by the company last year. While operating margins had taken a dip, sales had started showing signs of stagnation. Saddled with excess manufacturing facilities, labour force and low margin products, the leader was losing its hold in the market.

    After a year and a half of restructuring, GSK now seems to be lean, thin and rejuvenated organization with one clear mission statement in mind "Grow profits faster than sales and retain market leadership". The company has set itself the target of doubling its margins over the next three years.

    To achieve this target the company seems to be banking on a three-pronged strategy. Focus only on key brands and therapeutic segments, challenging the existing cost structure by exploring every possible cost rationalization strategy and leveraging on the marketing strength created over the years. The restructuring in terms of revenue rationalisation with an aim to improve margins is more or less through and the company is now in the midst of targeting costs across the entire spectrum. This would be achieved through increasing outsourcing, efficient procurement and organizational streamlining.

    After the merger with SmithKline Pharma, GSK has a very wide product portfolio covering a broad spectrum of therapeutic segments. The merged entity will target vaccines, dermatology, anti-infective and respiratory segments. We believe that vaccines would be a key area of growth for GSK. The company has several combinational vaccines where it enjoys monopoly position in the market. Even as far as other vaccines are concerned, the company’s products are priced at a premium compared to its peers.

    The product portfolio of the company has been rationalized and promotional resources would now be committed to only ‘strategic’ brands. It has reiterated its commitment to focus on recent launches where the company sees a huge penetration potential. The company’s product portfolio boasts of some leading brands in the pharma industry like Iodex, Zinetac, Septran, Betnesol, and Cobadex etc. The company enjoys brand equity among physicians coupled with an enviable distribution network.

    With little more than 50% of it’s sales coming from DPCO controlled products, the company is expected to be beneficiary of the current DPCO dilution. According to the new DPCO guidelines, Zinetac, Cobadex, Septran and Zevit are expected to come out of price control. This represents 15% of the total turnover of the company. However, Ceftum, its cephalosporin brand is expected to come under DPCO control, which represents around 5% of the company’s sales.

    Sensing the turnaround in financials, GSK stock has already seen a sharp rise in the last month. Valuations going forward may further improve as the company’s targeted efforts translate into bottom line growth for the company. Operating margins of the company have already shown an encouraging rise in the last quarter of FY02 and we expect a sharp spurt in margins in the current year. We expect GSK to record approximately 17% operating margins, a rise of more than 700 basis points.

    Further, we expect huge receipts to the company from sale of its (and its subsidiaries) excess properties. Since the company doesn’t have any expansion plans on the table currently, we expect huge one time dividend (in the range of Rs 50-55 per share) to shareholders from the sale of these properties.

    Having said that, we believe that the growth in the long term would be constrained by lack of new product introductions. Though the company’s product portfolio boosts of some very strong brand names in the Indian pharma market, the fact is that its portfolio is quite mature and faces stiff competition from domestic companies. At best, the company expects to grow inline with industry growth rates (7-8%), which in itself is not very attractive. To summarise, the restructuring benefits of the company are likely to translate into improving valuations in the short run, however, in the long run, concerns over growth remain.

     

     

    Equitymaster requests your view! Post a comment on "GSK India: The leader strikes back". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK PHARMA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GSK PHARMA

    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK PHARMA - MYLAN COMPARISON

    Compare Company With Charts

    COMPARE GSK PHARMA WITH

    MARKET STATS